Advancing Cancer Research and Accelerating Drug Development
The “Smart Innovation Platform for Preclinical Drug Development”, developed by Professor Shiow-Lin Pan’s research team at Taipei Medical University (TMU), leverages advanced AI technology to significantly reduce the time and costs for drug development.
The platform provides a faster, more accurate solution for developing inhibitors targeting severe illnesses such as cancer and neurodegenerative diseases.
The platform integrates AI models to predict chemical compound characteristicsaccurately, enabling rapid identification of effective small molecule inhibitors. To date, the team has successfully developed nearly 30 inhibitors targeting different protein targets, reducing the average development cycle by 3 to 5 years compared to conventional methods.
Core advantages of the platform:
Interdisciplinary AI Model Development: An expert team in chemical synthesis, artificial intelligence, pharmacology, and toxicology collaborated to build and train the AI model. By combining insights from extensive R&D experience, the platform effectively addresses the challenges of designing new drug candidates that are synthesizable, patentable, and biologically active.
Novel and Feasible Drug Structures: The smart innovative platform develop a smart synthesis strategy, which ensures AI-designed drug structures have an 80% synthesis probability, 60% cellular efficacy (IC50 < 10 µM), reduced synthesis costs by 90%, and optimized with real-time validation data from the experimental team.
The platform’s advantages lie in its ability to rapidly generate novel chemical structures with higher prediction accuracy, which benefits patients worldwide by significantly shortening the time needed for drug development.
Professor Pan highlighted that the Smart Innovation Platform offers high-success-rate, easily synthesizable, rapid, and precise early-stage drug development services and high-potential early-stage drug products for small-molecule development needs. The platform has been adopted by multiple academic research units and biotechnology companies globally, attracting recognition from international pharmaceutical companies.
Looking ahead, TMU’s team aims to enhance the platform’s capabilities and expand collaborations with pharmaceutical industries in Taiwan and globally. By accelerating the drug development process , the team hopes to bring transformative treatments to patients worldwide.
